ClinicalTrials.gg
TerminatedNCT03922100Updated Mar 18, 2026Results posted

Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

A Phase 1/2 interventional study of NMS-03592088 in Acute Myeloid Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML), sponsored by Nerviano Medical Sciences. Terminated at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Nerviano Medical Sciences · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Study stopped due to strategic reasons. The decision is not based on specific safety findings as the safety observed in the phase II part of the study is in line with what was reported in the phase I part.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
63
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 229 studies in Leukemia, Myeloid, Acute with a site in Italy — 45 open to participants now, 67 under way, 16 of them phase 3. Leukemia, Myeloid, Acute · Italy.

Enrollment
140th of 196
63 · median 120
Started
2019
with 19 others
Phase 1/2
41 of 229
6 open now
Registered
123rd of 229
by date

Among the 229 studies in Leukemia, Myeloid, Acute with a site in Italy, this one is the 140th largest by enrollment of the 196 interventional ones that give a count, is one of 20 that started in 2019, is one of 41 in phase 1/2, and was the 123rd registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

45 of the 229 studies in Leukemia, Myeloid, Acute with a site in Italy are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 229 studies in Leukemia, Myeloid, Acute with a site in Italy, or all of them as a file.
02

Study summary

The purpose of this study is to explore safety, tolerability, including the maximum tolerated dose and the recommended Phase II dose (RP2D), and antitumor activity of NMS-03592088 in adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML).

03

Conditions studied

  • Acute Myeloid Leukemia (AML)
  • Chronic Myelomonocytic Leukemia (CMML)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with disease who have failed standard therapy or are unsuitable for standard treatment, with one the following confirmed diagnosis: AML as defined by the European LeukemiaNet (ELN)
  • Patients with confirmed diagnosis of AML as defined by the 2022 ELN recommendations
  • Patients must have failed standard of care.
  • Adult (age ≥ 18 years) patients
  • (ECOG) performance status ≤ 2
  • The interval from prior antitumor treatment to time of NMS-03592088 administration should be at least 2 weeks for any agents other than hydroxyurea.
  • All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to version 5.0 Grade ≤1
  • Adequate hepatic and renal function
  • Patients must use highly effective .
  • Signed and dated IEC or IRB-approved form.

Exclusion criteria

Exclusion Criteria:

  • Current enrollment in another interventional clinical study
  • Diagnosis of acute promyelocytic leukemia or Breakpoint cluster region-Abelson (BCR-ABL)-positive leukaemia
  • Currently active second , except for adequately treated basal or squamous cell skin cancer and/or cone biopsied in situ carcinoma of the cervix uteri and/or superficial bladder cancer.
  • Patients with known leukemia involvement of central nervous system (CNS)
  • Hematopoietic stem cell transplantation () within 3 months of treatment start and/or persistent non-hematologic toxicities of Grade ≥2 related to the transplant
  • Active acute or chronic (GVHD) requiring treatment
  • Patients with interval ≥ 480 milliseconds or with risk factors for torsade de pointes
  • Pregnancy.
  • Breast-feeding or planning to breast feed during the study or within 3 months after study treatment.
  • Any of the following in the previous 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or , pulmonary embolism, deep vein thrombosis
  • Known active, life threatening or uncontrolled systemic infection.
  • Known active gastrointestinal disease
  • Known active gastrointestinal ulcer
  • Other severe or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation.
  • Known diagnosis of myasthenia gravis

US only:

  • Signs or symptoms of myasthenia gravis or stroke during screening
  • Patients with myasthenia gravis specific autoantibodies or any known history of myasthenia gravis (MG) autoantibodies at screening window
  • Concomitant medications with the potential to cause de novo myasthenia gravis, worsening of myasthenia gravis or cause myasthenia gravis-like symptoms
  • Uncontrolled hypertension, atrial fibrillation or flutter, ventricular arrhythmia or receiving treatment for cardiac rhythm disorder or diabetes that is not adequately controlled

Other protocol specific inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    NMS-03592088

    Phase I Dose Escalation * Schedule A - Starting dose of 20 mg/day * Schedule B - Starting dose of 120 mg/day Only one dose level open for enrollment except EU backfill cohorts. Phase II Dose Expansion (Exploratory) - (EU) Recommended Phase II Dose (RP2D) of NMS-03592088 in Phase 1 * Cohort 1: Patients who have failed standard of care including venetoclax and gilteritinib based therapies * Cohort 2: Patients who have failed standard of care

    Drug: NMS-03592088

Interventions

  • DrugNMS-03592088

    Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. Phase I - Number of Participants With Drug Related First-cycle Dose Limiting Toxicities (DLTs)

    DLTs were classified according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: From screening to end of first 28-days cycle (47 months)

  2. Phase II - Number of Participants Who Achieved Composite Complete Remission (CRc) Rate i.e. Complete Remission (CR) + Complete Remission With Incomplete Hematologic Recovery (CRi).

    CR = complete remission; CRc = composite complete remission rate; CRh = complete remission with partial hematologic recovery, CRi = complete remission with incomplete hematologic recovery; MLFS = morphologic leukemia free state; ORR = overall response rate; SD = stable disease Categories defined by the 2022 European LeukemiaNet (ELN) recommendations.

    Time frame: At Screening; Day 1 of Cycle 2 and Cycle 3; and Day 1 at subsequent even cycle; up to End of Treatment visit (within 7 days of the final dose of study drug), up to 17 months

Secondary outcomes

  1. Treatment-emergent Adverse Events (TEAEs) Graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] Version 5.0 Criteria

    TEAE with maximum Common Terminology Criteria (CTC) grade (graded by NCI CTCAE Version 5.0) experienced by each participant is presented. If an AE was reported for a participant more than once during treatment, the worst CTC Grade is presented here. Phase 2 started before Phase 1 completed. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 Life-threatening consequences; urgent intervention indicated.

    Time frame: Adverse events were collected from screening visit and assessed up to 18 months

  2. Pharmacokinetic Parameters: Maximum Plasma Concentration (Cmax), Last Measurable Concentration (Clast), and Average Concentration (Cavg) of NMS-03592088

    Plasma samples were collected and used for pharmacokinetics assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)

    Time frame: Schedule A: Day 1 and Day 21 Schedule B: Day 1 and Day 28

  3. Pharmacokinetic Parameters: Time to Maximum Plasma Concentration (Tmax), Time to Last Measurable Concentration (Tlast), and Terminal Elimination Half-life (t½,z) of NMS-03592088

    Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)

    Time frame: Schedule A: Day 1 and 21 Schedule B: Day 1 and 28

  4. Pharmacokinetic Parameter: Area Under the Concentration-time Curve to the Last Measurable Concentration (AUClast) and Area Under the Concentration-time Curve From Time Zero to 24 Hour (AUC0-24) of NMS-03592088

    Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)

    Time frame: Schedule A: Day 1 and Day 21 Schedule B: Day 1 and Day 28

  5. Pharmacokinetic Parameters: Apparent Volume of Distribution (V/F) and Apparent Volume of Distribution at Steady State (Vss/F)

    Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)

    Time frame: Schedule A: Day 21

  6. Pharmacokinetic Parameters: Apparent Plasma Clearance (CL/F) and Apparent Plasma Clearance at Steady State (CLss/F)

    Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)

    Time frame: Schedule A: Day 1 and Day 21 Schedule B: Day 1 and Day 28 CL/F: Evaluation of CL/F for Day 1 of all arms in Schedule A and Schedule B and Day 28 of Schedule B has not been performed

  7. Pharmacokinetic Parameters: Accumulation Ratios (RA) for AUC0-24 and Cmax

    Plasma samples were collected and used for pharmacokinetics assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%).

    Time frame: Schedule A: Day 21 Schedule B: Day 28 Evaluation of Accumulation ratios (RA) for AUC0-24 and Cmax on Day 1 of all arms in Schedule A and Schedule B has not been performed.

  8. Pharmacokinetic Parameters: Fraction Excreted Unchanged (FE) of NMS-03592088

    Urine samples were collected and used for pharmacokinetics (PK) assessments. Only cohorts with available data are presented. The assessment was performed only during the Phase I of the study. Mean values of PK parameters are presented with the coefficient of variation (CV%)

    Time frame: Schedule A: Day 21 Schedule B: Day 28 Evaluation of Fraction excreted unchanged (FE) for Arms 20, 40, 80, 120 and 180 mg of Schedule A and Arm 360+150 mg of Schedule B has not been performed.

  9. Best Response Rate for Participants With Acute Myeloblastic Leukemia (AML).

    For participants with AML diagnosis the number and percentage of participants with best response achieved on treatment in the following categories: CR, CRi, CRh, PR, MLFS, SD, No Response and Progressive Disease (PD). CR= complete response; CRh= Complete Remission with Partial Hematologic Recovery, CRi= Complete Remission with Incomplete Hematologic Recovery; CRc= Complete Remission Rate; MLFS= Morphologic leukemia free state; ORR= Overall Response Rate; PR= Partial Remission; SD= Stable Disease

    Time frame: From the date of treatment initiation up to end of study (approximately 1.5 years)

  10. For AML and in Phase II Only: Number of Participants Who Achieved Complete Remission (CR)

    Number of participants who achieved a CR as Best Response.

    Time frame: From the date of first response up to end of study (approximately 1.5 years)

  11. For AML and in Phase II Only: Complete Remission and Complete Remission With Partial Hematologic Recovery (CR/CRh) Rate

    Defined as the number of participants who achieved a CR or CRh or CRi as best response, divided by the number of participants in the analysis population.

    Time frame: From the date of first response up to end of study (approximately 1.5 years)

  12. For AML and in Phase II Only: Overall Response Rate (ORR: CRc + CRh + MLFS + PR)

    Defined as the number of participants who achieved CRi or MLFS as best response, divided by the number of participants in the analysis population.

    Time frame: From the date of first response up to end of study (approximately 1.5 years)

  13. Rate of Participants Bridged To Hemopoietic Stem Cell Transplantation

    Defined as proportion of participants bridged to hemopoietic stem cell transplantation

    Time frame: From the date of first response up to end of study (approximately 1.5 years)

07

Results

Posted Mar 18, 2026
Limitations and caveats
Study stopped due to strategic reasons. The decision was not based on specific safety findings as the safety observed in the phase II part of the study is in line with what was reported in the phase I part.

Participant flow

Participant flow — Overall Study
MilestonePhase 1, Schedule A: 20 mgPhase 1, Schedule A: 40 mgPhase 1, Schedule A: 80 mgPhase 1, Schedule A: 120 mgPhase 1, Schedule A: 180 mgPhase 1, Schedule A: 270 mgPhase 1, Schedule A: 300 mgPhase 1, Schedule A: 360 mgPhase 1, Schedule B: 120 mgPhase 1, Schedule B: 180 mgPhase 1, Schedule B: 250 mgPhase 2, Schedule B, Cohort 1:360+150 mgPhase 2, Schedule B, Cohort 2:360+150 mg
Started333334103464510
Completed0000000000000
Not completed333334103464510
Withdrew: Death0100000001212
Withdrew: Withdrawal by subject0000011001001
Withdrew: Study terminated by sponsor0000000000011
Withdrew: Disease progression or relapse3223218130214
Withdrew: Adverse event0010010012000
Withdrew: Physician decision0000110001010
Withdrew: Eligibility for hemopoietic stem cell transplantation0000001100001
Withdrew: First cycle dose limiting toxicity0000000101000
Withdrew: Unacceptable drug related toxicities incompatible with continuation of nms-035920880000000000010
Withdrew: Myasthenic syndrome with systemic and/or bulbar impairment0000000000001

Outcome measures

PrimaryPhase I - Number of Participants With Drug Related First-cycle Dose Limiting Toxicities (DLTs)

DLTs were classified according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.

Time frame:
From screening to end of first 28-days cycle (47 months)
Reported as:
Count of participants · Participants
Phase I - Number of Participants With Drug Related First-cycle Dose Limiting Toxicities (DLTs)
ParticipantsPhase 1, Schedule A: 20 mgPhase 1, Schedule A: 40 mgPhase 1, Schedule A: 80 mgPhase 1, Schedule A: 120 mgPhase 1, Schedule A: 180 mgPhase 1, Schedule A: 270 mgPhase 1, Schedule A: 300 mgPhase 1, Schedule A: 360 mgPhase 1, Schedule B: 120 mgPhase 1, Schedule B: 180 mgPhase 1, Schedule B: 250 mg
Phase I - Number of Participants With Drug Related First-cycle Dose Limiting Toxicities (DLTs)00000001010
PrimaryPhase II - Number of Participants Who Achieved Composite Complete Remission (CRc) Rate i.e. Complete Remission (CR) + Complete Remission With Incomplete Hematologic Recovery (CRi).

CR = complete remission; CRc = composite complete remission rate; CRh = complete remission with partial hematologic recovery, CRi = complete remission with incomplete hematologic recovery; MLFS = morphologic leukemia free state; ORR = overall response rate; SD = stable disease Categories defined by the 2022 European LeukemiaNet (ELN) recommendations.

Time frame:
At Screening; Day 1 of Cycle 2 and Cycle 3; and Day 1 at subsequent even cycle; up to End of Treatment visit (within 7 days of the final dose of study drug), up to 17 months
Reported as:
Count of participants · Participants
Phase II - Number of Participants Who Achieved Composite Complete Remission (CRc) Rate i.e. Complete Remission (CR) + Complete Remission With Incomplete Hematologic Recovery (CRi).
ParticipantsPhase 2, Schedule B, Cohort 1:360+150 mgPhase 2, Schedule B, Cohort 2: 360+150 mg
Phase II - Number of Participants Who Achieved Composite Complete Remission (CRc) Rate i.e. Complete Remission (CR) + Complete Remission With Incomplete Hematologic Recovery (CRi).01
SecondaryTreatment-emergent Adverse Events (TEAEs) Graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] Version 5.0 Criteria

TEAE with maximum Common Terminology Criteria (CTC) grade (graded by NCI CTCAE Version 5.0) experienced by each participant is presented. If an AE was reported for a participant more than once during treatment, the worst CTC Grade is presented here. Phase 2 started before Phase 1 completed. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 Life-threatening consequences; urgent intervention indicated.

Time frame:
Adverse events were collected from screening visit and assessed up to 18 months
Reported as:
Count of participants · Participants
Treatment-emergent Adverse Events (TEAEs) Graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] Version 5.0 Criteria
ParticipantsPhase 1, Schedule A: 20 mgPhase 1, Schedule A: 40 mgPhase 1, Schedule A: 80 mgPhase 1, Schedule A: 120 mgPhase 1, Schedule A: 180 mgPhase 1, Schedule A: 270 mgPhase 1, Schedule A: 300 mgPhase 1, Schedule A: 360 mgPhase 1, Schedule B: 120 mgPhase 1, Schedule B: 180 mgPhase 1, Schedule B: 250 mgPhase 2, Schedule B:360+150 mg
Treatment-emergent Adverse Events (TEAEs) Graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] Version 5.0 Criteria33333410346415
SecondaryPharmacokinetic Parameters: Maximum Plasma Concentration (Cmax), Last Measurable Concentration (Clast), and Average Concentration (Cavg) of NMS-03592088

Plasma samples were collected and used for pharmacokinetics assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)

Time frame:
Schedule A: Day 1 and Day 21 Schedule B: Day 1 and Day 28
Reported as:
Mean · μM
Pharmacokinetic Parameters: Maximum Plasma Concentration (Cmax), Last Measurable Concentration (Clast), and Average Concentration (Cavg) of NMS-03592088
μMPhase 1, Schedule A: 20 mgPhase 1, Schedule A: 40 mgPhase 1, Schedule A: 80 mgPhase 1, Schedule A: 120 mgPhase 1, Schedule A: 180 mgPhase 1, Schedule A: 270 mgPhase 1, Schedule A: 300 mgPhase 1, Schedule A: 360 mgPhase 1, Schedule B: 120 mgPhase 1, Schedule B: 180 mgPhase 1, Schedule B: 250 mgPhase 2, Schedule B: 360+150 mg
Cmax: Day 10.00469 ± 12.90.0174 ± 19.10.0262 ± 33.60.0388 ± 53.10.118 ± 43.90.211 ± 84.20.207 ± 55.50.240 ± 79.80.0907 ± 82.40.124 ± 42.90.183 ± 51.10.0995 ± 43.9
Cmax: Day 210.0523 ± 52.50.0526 ± 32.40.0896 ± 22.60.125 ± 45.90.320 ± 64.00.553 ± 41.90.444 ± 50.60.467 ± 40.9————
Cmax: Day 28————————0.266 ± 42.00.354 ± 46.50.462 ± 54.40.168 ± 37.7
Clast: Day 10.00363 ± 38.20.00819 ± 55.50.0132 ± 19.00.0188 ± 45.70.0309 ± 52.30.0568 ± 46.50.137 ± 68.80.0930 ± 75.70.0296 ± 37.20.0536 ± 79.40.0957 ± 19.70.0816 ± 43.6
Clast: Day 210.0151 ± 59.70.00902 ± 1020.0199 ± 77.20.0230 ± 81.40.0548 ± 48.70.0876 ± 20.10.0831 ± 86.90.215 ± 80.9————
Clast: Day 28————————0.141 ± 39.50.293 ± 53.10.322 ± 53.30.116 ± 20.3
Cavg: Day 10.00385 ± 19.90.0102 ± 32.90.0168 ± 22.90.0230 ± 34.10.0591 ± 65.90.0931 ± 54.10.0905 ± 61.20.143 ± 78.60.0455 ± 61.50.0554 ± 27.90.0883 ± 61.10.0172 ± 46.4
Cavg: Day 210.0423 ± 41.30.0392 ± 56.30.0740 ± 30.20.0890 ± 32.00.200 ± 37.30.421 ± 27.10.349 ± 50.40.351 ± 54.6————
Cavg: Day 28————————0.183 ± 36.10.277 ± 48.20.378 ± 56.20.118 ± 69.8
SecondaryPharmacokinetic Parameters: Time to Maximum Plasma Concentration (Tmax), Time to Last Measurable Concentration (Tlast), and Terminal Elimination Half-life (t½,z) of NMS-03592088

Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)

Time frame:
Schedule A: Day 1 and 21 Schedule B: Day 1 and 28
Reported as:
Mean · hour
Pharmacokinetic Parameters: Time to Maximum Plasma Concentration (Tmax), Time to Last Measurable Concentration (Tlast), and Terminal Elimination Half-life (t½,z) of NMS-03592088
hourPhase 1, Schedule A: 20 mgPhase 1, Schedule A: 40 mgPhase 1, Schedule A: 80 mgPhase 1, Schedule A: 120 mgPhase 1, Schedule A: 180 mgPhase 1, Schedule A: 270 mgPhase 1, Schedule A: 300 mgPhase 1, Schedule A: 360 mgPhase 1, Schedule B: 120 mgPhase 1, Schedule B: 180 mgPhase 1, Schedule B: 250 mgPhase 2, Schedule B: 360+150 mg
Tmax: Day 16.00 ± 03.33 ± 69.310.4 ± 90.43.01 ± 87.71.67 ± 35.03.02 ± 65.83.78 ± 41.74.66 ± 24.44.00 ± 57.73.65 ± 41.73.25 ± 83.92.73 ± 46.5
Tmax: Day 211.67 ± 1253.00 ± 88.24.00 ± 50.03.33 ± 69.39.31 ± 1364.00 ± 44.75.41 ± 1084.41 ± 37.7————
Tmax: Day 28————————2.33 ± 58.66.00 ± 49.52.80 ± 63.94.33 ± 34.7
Tlast: Day 123.5 ± 1.0522.5 ± 3.2321.1 ± 11.922.7 ± 7.1522.6 ± 13.023.4 ± 2.1416.4 ± 50.622.4 ± 6.7823.2 ± 2.7920.0 ± 34.818.5 ± 45.65.96 ± 1.29
Tlast: Day 21160 ± 35.2194 ± 0.998170 ± 25.4170 ± 43.8120 ± 39.7160 ± 31.1183 ± 26.6120 ± 60.2————
Tlast: Day 28————————24.0 ± 022.0 ± 22.824.0 ± 0.30917.9 ± 57.5
t½,z: Day 1NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
t½,z: Day 2189.5 ± 19.579.5 ± 35.271.7 ± 4.3568.4 ± 18.257.3 ± 32.363.7 ± 24.077.3 ± 16.4150 ± 0————
t½,z: Day 28————————NA ± NANA ± NANA ± NANA ± NA
SecondaryPharmacokinetic Parameter: Area Under the Concentration-time Curve to the Last Measurable Concentration (AUClast) and Area Under the Concentration-time Curve From Time Zero to 24 Hour (AUC0-24) of NMS-03592088

Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)

Time frame:
Schedule A: Day 1 and Day 21 Schedule B: Day 1 and Day 28
Reported as:
Mean · h·μM
Pharmacokinetic Parameter: Area Under the Concentration-time Curve to the Last Measurable Concentration (AUClast) and Area Under the Concentration-time Curve From Time Zero to 24 Hour (AUC0-24) of NMS-03592088
h·μMPhase 1, Schedule A: 20 mgPhase 1, Schedule A: 40 mgPhase 1, Schedule A: 80 mgPhase 1, Schedule A: 120 mgPhase 1, Schedule A: 180 mgPhase 1, Schedule A: 270 mgPhase 1, Schedule A: 300 mgPhase 1, Schedule A: 360 mgPhase 1, Schedule B: 120 mgPhase 1, Schedule B: 180 mgPhase 1, Schedule B: 250 mgPhase 2, Schedule B: 360+150 mg
AUClast: Day 10.0923 ± 19.90.244 ± 32.90.402 ± 22.90.551 ± 34.11.43 ± 66.72.23 ± 54.12.17 ± 61.23.44 ± 78.61.09 ± 61.51.33 ± 27.92.12 ± 60.80.412 ± 46.4
AUClast: Day 214.10 ± 53.33.96 ± 71.96.31 ± 29.06.98 ± 35.313.4 ± 54.434.5 ± 28.231.4 ± 59.123.7 ± 80.1————
AUClast: Day 28————————4.39 ± 36.16.67 ± 48.79.09 ± 56.52.84 ± 69.9
AUC0-24: Day 10.0923 ± 19.90.244 ± 32.90.402 ± 22.90.551 ± 34.11.42 ± 65.92.23 ± 54.12.17 ± 61.23.44 ± 78.61.09 ± 61.51.33 ± 27.92.12 ± 61.10.412 ± 46.4
AUC0-24: Day 211.02 ± 41.30.941 ± 56.31.78 ± 30.22.14 ± 32.04.80 ± 37.310.1 ± 27.18.37 ± 50.48.43 ± 54.6————
AUC0-24: Day 28————————4.39 ± 36.16.65 ± 48.29.07 ± 56.22.83 ± 69.8
SecondaryPharmacokinetic Parameters: Apparent Volume of Distribution (V/F) and Apparent Volume of Distribution at Steady State (Vss/F)

Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)

Time frame:
Schedule A: Day 21
Reported as:
Mean · L
Pharmacokinetic Parameters: Apparent Volume of Distribution (V/F) and Apparent Volume of Distribution at Steady State (Vss/F)
LPhase 1, Schedule A: 20 mgPhase 1, Schedule A: 40 mgPhase 1, Schedule A: 80 mgPhase 1, Schedule A: 120 mgPhase 1, Schedule A: 180 mgPhase 1, Schedule A: 270 mgPhase 1, Schedule A: 300 mgPhase 1, Schedule A: 360 mgPhase 1, Schedule B: 120 mgPhase 1, Schedule B: 180 mgPhase 1, Schedule B: 250 mgPhase 2, Schedule B:360+150 mg
V/F: Day 21844 ± 32.52030 ± 39.71940 ± 31.32680 ± 50.91630 ± 31.01070 ± 17.51770 ± 36.01070 ± 0————
Vss/F: Day 214880 ± 21.89440 ± 20.38800 ± 22.810900 ± 39.45810 ± 25.84710 ± 37.08270 ± 37.010500 ± 0————
SecondaryPharmacokinetic Parameters: Apparent Plasma Clearance (CL/F) and Apparent Plasma Clearance at Steady State (CLss/F)

Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)

Time frame:
Schedule A: Day 1 and Day 21 Schedule B: Day 1 and Day 28 CL/F: Evaluation of CL/F for Day 1 of all arms in Schedule A and Schedule B and Day 28 of Schedule B has not been performed
Reported as:
Mean · L/h
Pharmacokinetic Parameters: Apparent Plasma Clearance (CL/F) and Apparent Plasma Clearance at Steady State (CLss/F)
L/hPhase 1, Schedule A: 20 mgPhase 1, Schedule A: 40 mgPhase 1, Schedule A: 80 mgPhase 1, Schedule A: 120 mgPhase 1, Schedule A: 180 mgPhase 1, Schedule A: 270 mgPhase 1, Schedule A: 300 mgPhase 1, Schedule A: 360 mgPhase 1, Schedule B: 120 mgPhase 1, Schedule B: 180 mgPhase 1, Schedule B: 250 mgPhase 2, Schedule B:360+150 mg
CL/F: Day 1NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
CL/F: Day 217.02 ± 53.120.4 ± 57.119.0 ± 34.627.6 ± 52.521.4 ± 46.512.1 ± 26.316.8 ± 46.54.94 ± 0————
CL/F: Day 28————————NA ± NANA ± NANA ± NANA ± NA
CLss/F: Day 1399 ± 19.9318 ± 32.2372 ± 23.3434 ± 41.6301 ± 57.5264 ± 44.7477 ± 117502 ± 126317 ± 89.3263 ± 31.4359 ± 97.11820 ± 45.0
CLss/F: Day 2139.9 ± 40.891.2 ± 42.585.7 ± 26.3110 ± 38.674.7 ± 38.750.9 ± 23.177.8 ± 38.498.2 ± 50.4————
CLss/F: Day 28————————57.4 ± 46.856.3 ± 35.563.8 ± 52.7209 ± 117
SecondaryPharmacokinetic Parameters: Accumulation Ratios (RA) for AUC0-24 and Cmax

Plasma samples were collected and used for pharmacokinetics assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%).

Time frame:
Schedule A: Day 21 Schedule B: Day 28 Evaluation of Accumulation ratios (RA) for AUC0-24 and Cmax on Day 1 of all arms in Schedule A and Schedule B has not been performed.
Reported as:
Mean · Ratio
Pharmacokinetic Parameters: Accumulation Ratios (RA) for AUC0-24 and Cmax
RatioPhase 1, Schedule A: 20 mgPhase 1, Schedule A: 40 mgPhase 1, Schedule A: 80 mgPhase 1, Schedule A: 120 mgPhase 1, Schedule A: 180 mgPhase 1, Schedule A: 270 mgPhase 1, Schedule A: 300 mgPhase 1, Schedule A: 360 mgPhase 1, Schedule B: 120 mgPhase 1, Schedule B: 180 mgPhase 1, Schedule B: 250 mgPhase 2, Schedule B:360+150 mg
RA, AUC0-24: Day 218.99 ± 46.93.72 ± 26.04.42 ± 18.33.91 ± 9.884.14 ± 50.24.48 ± 32.15.78 ± 85.64.92 ± 66.0————
RA, AUC0-24: Day 28————————6.14 ± 33.95.81 ± 42.93.40 ± 36.99.33 ± 85.5
RA, Cmax: Day 218.26 ± 49.13.08 ± 33.73.74 ± 42.53.54 ± 38.42.86 ± 69.43.07 ± 59.32.73 ± 52.54.06 ± 69.0————
RA, Cmax: Day 28————————6.19 ± 44.43.75 ± 55.32.59 ± 29.62.13 ± 70.7
SecondaryPharmacokinetic Parameters: Fraction Excreted Unchanged (FE) of NMS-03592088

Urine samples were collected and used for pharmacokinetics (PK) assessments. Only cohorts with available data are presented. The assessment was performed only during the Phase I of the study. Mean values of PK parameters are presented with the coefficient of variation (CV%)

Time frame:
Schedule A: Day 21 Schedule B: Day 28 Evaluation of Fraction excreted unchanged (FE) for Arms 20, 40, 80, 120 and 180 mg of Schedule A and Arm 360+150 mg of Schedule B has not been performed.
Reported as:
Mean · percentage
Pharmacokinetic Parameters: Fraction Excreted Unchanged (FE) of NMS-03592088
percentagePhase 1, Schedule A: 20 mgPhase 1, Schedule A: 40 mgPhase 1, Schedule A: 80 mgPhase 1, Schedule A: 120 mgPhase 1, Schedule A: 180 mgPhase 1, Schedule A: 270 mgPhase 1, Schedule A: 300 mgPhase 1, Schedule A: 360 mgPhase 1, Schedule B: 120 mgPhase 1, Schedule B: 180 mgPhase 1, Schedule B: 250 mgPhase 2, Schedule B:360+150 mg
Day 21—————0.0321 ± 76.40.0396 ± 1370.0812 ± 49.4————
Day 28————————0.0301 ± 42.20.0577 ± 67.40.0299 ± 44.9—
SecondaryBest Response Rate for Participants With Acute Myeloblastic Leukemia (AML).

For participants with AML diagnosis the number and percentage of participants with best response achieved on treatment in the following categories: CR, CRi, CRh, PR, MLFS, SD, No Response and Progressive Disease (PD). CR= complete response; CRh= Complete Remission with Partial Hematologic Recovery, CRi= Complete Remission with Incomplete Hematologic Recovery; CRc= Complete Remission Rate; MLFS= Morphologic leukemia free state; ORR= Overall Response Rate; PR= Partial Remission; SD= Stable Disease

Time frame:
From the date of treatment initiation up to end of study (approximately 1.5 years)
Reported as:
Count of participants · Participants
Best Response Rate for Participants With Acute Myeloblastic Leukemia (AML).
ParticipantsPhase 1, Schedule A: 20 mgPhase 1, Schedule A: 40 mgPhase 1, Schedule A: 80 mgPhase 1, Schedule A: 120 mgPhase 1, Schedule A: 180 mgPhase 1, Schedule A: 270 mgPhase 1, Schedule A: 300 mgPhase 1, Schedule A: 360 mgPhase 1, Schedule B: 120 mgPhase 1, Schedule B: 180 mgPhase 1, Schedule B: 250 mgPhase 2, Schedule B, Cohort 1:360+150 mgPhase 2, Schedule B, Cohort 2: 360+150 mg
No Response/SD0000000046436
CRc: CR + CRi0000000000001
CR+CRh+CRi0000000000001
ORR:CR+CRh+CRi+MLFS+PR0000000000003
CRi0000001200001
MLFS0000002000002
SecondaryFor AML and in Phase II Only: Number of Participants Who Achieved Complete Remission (CR)

Number of participants who achieved a CR as Best Response.

Time frame:
From the date of first response up to end of study (approximately 1.5 years)
Reported as:
Count of participants · Participants
For AML and in Phase II Only: Number of Participants Who Achieved Complete Remission (CR)
ParticipantsPhase 2, Schedule B, Cohort 1:360+150 mgPhase 2, Schedule B, Cohort 2: 360+150 mg
For AML and in Phase II Only: Number of Participants Who Achieved Complete Remission (CR)00
SecondaryFor AML and in Phase II Only: Complete Remission and Complete Remission With Partial Hematologic Recovery (CR/CRh) Rate

Defined as the number of participants who achieved a CR or CRh or CRi as best response, divided by the number of participants in the analysis population.

Time frame:
From the date of first response up to end of study (approximately 1.5 years)
Reported as:
Count of participants · Participants
For AML and in Phase II Only: Complete Remission and Complete Remission With Partial Hematologic Recovery (CR/CRh) Rate
ParticipantsPhase 2, Schedule B, Cohort 1:360+150 mgPhase 2, Schedule B, Cohort 2: 360+150 mg
For AML and in Phase II Only: Complete Remission and Complete Remission With Partial Hematologic Recovery (CR/CRh) Rate00
SecondaryFor AML and in Phase II Only: Overall Response Rate (ORR: CRc + CRh + MLFS + PR)

Defined as the number of participants who achieved CRi or MLFS as best response, divided by the number of participants in the analysis population.

Time frame:
From the date of first response up to end of study (approximately 1.5 years)
Reported as:
Count of participants · Participants
For AML and in Phase II Only: Overall Response Rate (ORR: CRc + CRh + MLFS + PR)
ParticipantsPhase 2, Schedule B, Cohort 1:360+150 mgPhase 2, Schedule B, Cohort 2: 360+150 mg
For AML and in Phase II Only: Overall Response Rate (ORR: CRc + CRh + MLFS + PR)03
SecondaryRate of Participants Bridged To Hemopoietic Stem Cell Transplantation

Defined as proportion of participants bridged to hemopoietic stem cell transplantation

Time frame:
From the date of first response up to end of study (approximately 1.5 years)
Reported as:
Count of participants · Participants
Rate of Participants Bridged To Hemopoietic Stem Cell Transplantation
ParticipantsPhase 2, Schedule B, Cohort 1:360+150 mgPhase 2, Schedule B, Cohort 2: 360+150 mg
Rate of Participants Bridged To Hemopoietic Stem Cell Transplantation01

Adverse events

Collected over Adverse events were collected from screening visit and assessed up to 18 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1, Schedule A: 20 mg3/3 (100%)0/3 (0%)3/3 (100%)
Phase 1, Schedule A: 40 mg3/3 (100%)2/3 (66.7%)3/3 (100%)
Phase 1, Schedule A: 80 mg3/3 (100%)2/3 (66.7%)3/3 (100%)
Phase 1, Schedule A: 120 mg3/3 (100%)0/3 (0%)3/3 (100%)
Phase 1, Schedule A: 180 mg3/3 (100%)2/3 (66.7%)3/3 (100%)
Phase 1, Schedule A: 270 mg4/4 (100%)3/4 (75%)4/4 (100%)
Phase 1, Schedule A: 300 mg9/10 (90%)8/10 (80%)10/10 (100%)
Phase 1, Schedule A: 360 mg3/3 (100%)3/3 (100%)3/3 (100%)
Phase 1, Schedule B: 120 mg4/4 (100%)4/4 (100%)4/4 (100%)
Phase 1, Schedule B: 180 mg6/6 (100%)6/6 (100%)6/6 (100%)
Phase 1, Schedule B: 250 mg4/4 (100%)4/4 (100%)3/4 (75%)
Phase 2, Schedule B: 360-150 mg9/15 (60%)14/15 (93.3%)14/15 (93.3%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventPhase 1, Schedule A: 20 mgPhase 1, Schedule A: 40 mgPhase 1, Schedule A: 80 mgPhase 1, Schedule A: 120 mgPhase 1, Schedule A: 180 mgPhase 1, Schedule A: 270 mgPhase 1, Schedule A: 300 mgPhase 1, Schedule A: 360 mgPhase 1, Schedule B: 120 mgPhase 1, Schedule B: 180 mgPhase 1, Schedule B: 250 mgPhase 2, Schedule B: 360-150 mg
Upper gastrointestinal haemorrhageGastrointestinal disorders0/30/30/30/30/32/40/102/30/41/60/42/15
Disease progressionGeneral disorders0/30/30/30/31/30/41/101/32/40/61/41/15
Febrile neutropeniaBlood and lymphatic system disorders0/30/30/30/30/30/42/100/30/42/61/44/15
DiplopiaEye disorders0/30/30/30/31/30/40/100/30/40/60/40/15
Decreased activityGeneral disorders0/30/30/30/30/30/40/101/30/40/60/40/15
PyrexiaGeneral disorders0/30/30/30/31/30/41/100/30/40/60/40/15
Bronchopulmonary aspergillosisInfections and infestations0/30/30/30/31/31/40/100/30/40/60/40/15
Lung infectionInfections and infestations0/31/30/30/30/30/42/100/31/40/60/40/15
PharyngitisInfections and infestations0/30/30/30/31/30/40/100/30/40/60/40/15
PneumoniaInfections and infestations0/30/31/30/30/31/40/100/30/40/60/42/15
Most frequent other events
Showing 10 of 225
Most frequent other events
EventPhase 1, Schedule A: 20 mgPhase 1, Schedule A: 40 mgPhase 1, Schedule A: 80 mgPhase 1, Schedule A: 120 mgPhase 1, Schedule A: 180 mgPhase 1, Schedule A: 270 mgPhase 1, Schedule A: 300 mgPhase 1, Schedule A: 360 mgPhase 1, Schedule B: 120 mgPhase 1, Schedule B: 180 mgPhase 1, Schedule B: 250 mgPhase 2, Schedule B: 360-150 mg
AnaemiaBlood and lymphatic system disorders1/30/33/31/31/32/42/101/30/42/60/40/15
PyrexiaGeneral disorders2/30/32/30/31/31/40/103/32/42/63/45/15
HyperphosphataemiaMetabolism and nutrition disorders0/30/33/30/30/31/40/100/31/40/60/41/15
AstheniaGeneral disorders0/30/30/30/31/32/45/101/33/41/62/42/15
LeukocytosisBlood and lymphatic system disorders2/31/31/30/30/31/41/100/30/41/60/40/15
NeutropeniaBlood and lymphatic system disorders0/30/32/30/32/30/40/101/32/41/60/41/15
ThrombocytopeniaBlood and lymphatic system disorders0/31/32/31/31/32/41/102/30/42/61/42/15
Sinus tachycardiaCardiac disorders0/30/32/30/30/30/40/100/30/40/60/40/15
Abdominal pain upperGastrointestinal disorders2/30/32/30/32/30/41/101/31/40/60/41/15
ConstipationGastrointestinal disorders0/30/32/31/31/31/41/101/30/41/60/42/15

Baseline characteristics

Treated Participants: This population consisted of all enrolled participants who actually received at least 1 dose of study drug administration. This population was used for subject disposition, baseline characteristics, treatment exposure, efficacy, and safety. It is different from Participant Flow.

Age, Categorical
Age, Categorical(Participants)Phase 1, Schedule A: 20 mgPhase 1, Schedule A: 40 mgPhase 1, Schedule A: 80 mgPhase 1, Schedule A: 120 mgPhase 1, Schedule A: 180 mgPhase 1, Schedule A: 270 mgPhase 1, Schedule A: 300 mgPhase 1, Schedule A: 360 mgPhase 1, Schedule B: 120 mgPhase 1, Schedule B: 180 mgPhase 1, Schedule B: 250 mgPhase 2, Schedule B, Cohort 1:360+150 mgPhase 2, Schedule B, Cohort 2: 360+150 mgTotal
<=18 years00000000000000
Between 18 and 65 years202103922122632
>=65 years131231112523429
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1, Schedule A: 20 mgPhase 1, Schedule A: 40 mgPhase 1, Schedule A: 80 mgPhase 1, Schedule A: 120 mgPhase 1, Schedule A: 180 mgPhase 1, Schedule A: 270 mgPhase 1, Schedule A: 300 mgPhase 1, Schedule A: 360 mgPhase 1, Schedule B: 120 mgPhase 1, Schedule B: 180 mgPhase 1, Schedule B: 250 mgPhase 2, Schedule B, Cohort 1:360+150 mgPhase 2, Schedule B, Cohort 2: 360+150 mgTotal
Female122121522205530
Male211213512440531
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1, Schedule A: 20 mgPhase 1, Schedule A: 40 mgPhase 1, Schedule A: 80 mgPhase 1, Schedule A: 120 mgPhase 1, Schedule A: 180 mgPhase 1, Schedule A: 270 mgPhase 1, Schedule A: 300 mgPhase 1, Schedule A: 360 mgPhase 1, Schedule B: 120 mgPhase 1, Schedule B: 180 mgPhase 1, Schedule B: 250 mgPhase 2, Schedule B, Cohort 1:360+150 mgPhase 2, Schedule B, Cohort 2: 360+150 mgTotal
American Indian or Alaska Native00000000000000
Asian00000000000000
Native Hawaiian or Other Pacific Islander00000000000000
Black or African American00000000000000
White2333341034644958
More than one race00000000000000
Unknown or Not Reported10000000000113
(Eastern Cooperative Oncology Group Performance Status (ECOG-PS)
(Eastern Cooperative Oncology Group Performance Status (ECOG-PS)(participants)Phase 1, Schedule A: 20 mgPhase 1, Schedule A: 40 mgPhase 1, Schedule A: 80 mgPhase 1, Schedule A: 120 mgPhase 1, Schedule A: 180 mgPhase 1, Schedule A: 270 mgPhase 1, Schedule A: 300 mgPhase 1, Schedule A: 360 mgPhase 1, Schedule B: 120 mgPhase 1, Schedule B: 180 mgPhase 1, Schedule B: 250 mgPhase 2, Schedule B, Cohort 1:360+150 mgPhase 2, Schedule B, Cohort 2: 360+150 mgTotal
ECOG PS = 0011032403221423
ECOG PS = 1322301531412532
ECOG PS = 200000110001216
08

Study locations

11 sites
  • Centre Hospitalier du Mans
    Le Mans, 72037, France
  • Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu
    Nantes, 44000, France
  • CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque
    Pessac, 33604, France
  • Centre Hospitalier Lyon-Sud
    Pierre-Bénite, 69495, France
  • ASST Papa Giovanni XXIII
    Bergamo, BG 24127, Italy
  • ASST Grande Ospedale Metropolitano Niguarda
    Milan, MI 20162, Italy
  • Istituto Clinico Humanitas
    Rozzano, MI 20089, Italy
  • Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi
    Bologna, 40138, Italy
  • ASST Spedali Civili di Brescia
    Brescia, 25123, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli
    Roma, 00168, Italy
  • Hospital Universitari i Politècnic La Fe
    Valencia, 46026, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Aug 2024, 64 months.

Results were first posted in Mar 2026, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2019
First posted
Apr 19, 2019
StartActual
Apr 3, 2019
Primary completionActual
Aug 29, 2024
CompletionActual
Aug 29, 2024
Results first posted
Mar 18, 2026
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03922100
Lead sponsor
Nerviano Medical Sciences
Responsible party
Sponsor
First posted
Apr 19, 2019
Start date
Apr 3, 2019
Primary completion
Aug 29, 2024
Completion
Aug 29, 2024
Results posted
Mar 18, 2026
Last update
Mar 18, 2026

Study contacts

Alessandro Rambaldi, MD
principal investigator · ASST Papa Giovanni XXIII

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion